Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
glutamate-cysteine ligase
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "glutamate-cysteine ligase" in MCE Product Catalog:
Target:
Target:
Research Areas:
Keap1-Nrf2-IN-9 (Compound 11) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein-protein interaction) inhibitor with an IC50 of 0.575 μM. Keap1-Nrf2-IN-9 increases the expression of Nrf2 target genes including heme oxygenase 1 (Hmox1), glutathione S-transferase P (GstP), and glutamate-cysteine ligase catalytic (Gclc) and modulatory (Gclm) subunits. Keap1-Nrf2-IN-9 shows no cytotoxic activity in ARPE19 cells .
Cat. No.: HY-126752A
Target:
Research Areas:
Ophthalmic acid TFA is a ubiquitous metabolite and glutathione modulator, with a Ki of 0.95 mM for glyoxalase I. Ophthalmic acid TFA competitively inhibits glyoxalase I, glutathione S-transferase, glutaredoxin, glutamate-cysteine ligase, protein disulfide reductase (glutathione), as well as non-selective cation channels. Ophthalmic acid TFA is applicable in diabetes-related research .
Cat. No.: HY-126752R
CAS No.: 495-27-2
Cat. No.: HY-P81662
Synonyms: GCLM; GLCLR; glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-glutamylcysteine synthetase regulatory subunit; glutamate--cysteine ligase modifier subunit
Cat. No.: HY-P86557
Synonyms: GCLM; GLCLR; glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-glutamylcysteine synthetase regulatory subunit; glutamate--cysteine ligase modifier subunit
Cat. No.: HY-184266
CAS No.: 2926699-71-8
Synonyms: ONO-6428513
Target:
Research Areas:
GCLCi0 (ONO-6428513) is a glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer that blocks the rate-limiting step of glutathione synthesis and exerts anti-tumor activity. GCLCi0 specifically targets SMARCB1-deficient cancer cells, induces reactive oxygen species production and lipid peroxidation. In addition, GCLCi0 shows a significant synergistic effect with SLC7A11 inhibitors and Telaglenastat (HY-12248). GCLCi0 can be used in the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas .
Cat. No.: HY-184267
CAS No.: 2926699-78-5
Synonyms: ONO-7068506
Research Areas:
GCLCi1 is an orally active glutamate-cysteine ligase catalytic subunit (GCLC) inhibitor and ferroptosis inducer. GCLCi1 blocks the rate-limiting step of glutathione synthesis, leading to GSH depletion, elevated reactive oxygen species and lipid peroxidation. GCLCi1 exhibits high selectivity for SMARCB1 -deficient cancer cells and possesses anti-tumor activity. In addition, the combination of GCLCi1 with SLC7A11 inhibitors and Telaglenastat (HY-12248) produces a synergistic effect, which can be used for the research of smarcb1-deficient malignant rhabdoid tumors and smarcb1-deficient epithelioid sarcomas .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
